ClinicalTrials.gg
RecruitingNCT06409936PEARLUpdated Jul 8, 2025

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

A Phase 2 interventional study of Asciminib and Nilotinib in CML, Chronic Phase, Chronic Myeloid Leukemia, Chronic Phase and Chronic Myeloid Leukemia, BCR/ABL-Positive, sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto. Recruiting at 11 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-08.

Primary conditionLeukemia, Myelogenous, Chronic, BCR-ABL PositiveRegistry: Leukemia, Myeloid, Chronic-PhaseReclassifiedWhy we changed it
Registry
Leukemia, Myeloid, Chronic-Phase — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Why
  1. Leukemia, Myeloid, Chronic-Phase is a broad heading, used only when no more specific condition is named.
  2. The study's listed conditions name Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 7 open to participants now, 13 under way, 2 of them phase 3. asciminib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Planned enrollment
7th of 21
160 · median 100
Started
2025
with 1 other
Phase 2
11 of 21
6 open now
Primary completion
2029-06
later than 7 of 12 live
Registered
17th of 21
by date
Lead sponsor
1 of 21
Gruppo Italiano Malattie EMatologiche dell'Adulto

Among the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 7th largest by planned enrollment, is one of 2 that started in 2025, is one of 11 in phase 2, reaches primary completion later than 7 of the 12 other live ones, and was the 17th registered.

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Open to participants now

7 of the 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About asciminib

asciminib: first FDA approval 2021 (SCEMBLIX), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing asciminib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, or all of them as a file.
02

Study summary

A phase 2, interventional, randomized unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80 mg QD as single agent (arm A) or 40 mg BID in combination with nilotinib 300 mg BID (arm B).

All patients in both arm A and arm B will be treated for a minimum of 2 years (core phase). If they will have achieved a DMR (MR4), or if it will be in the interest of the patient, the treatment will be continued.

During the consolidation phase (2 years) asciminib will be continued at the same dose in both arms; in the combination arm the nilotinib dose will be reduced to 300 mg daily.

The patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment (TFR phase). The rate of TFR at 5 year (1 year after discontinuation) will be evaluated.

Read the detailed description

A phase 2, prospective, interventional, randomized (two arms, randomization 1:1), unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80 mg QD as single agent (arm A) or 40 mg BID in combination with nilotinib 300 mg BID (arm B).

  • In the arm A, asciminib 80 mg QD will be given as single-agent. In the arm B, asciminib 80 mg QD will be started, then after 90 days asciminib will be given 40 mg BID and nilotinib 300 mg BID, or 300 mg OAD according to the presence/absence of asciminib adverse events, will be added-on in all patients. All patients in both arm A and arm B will be treated for a minimum of 2 years (core phase). If they will have achieved a DMR (MR4), or if it will be in the interest of the patient, the treatment will be continued. In both arms the study drugs may be discontinued at any time for inefficacy (failure) or safety reasons(grade 3-4 toxicity or persistent grade 2 non hematologic toxicity). However, all the patient will remain "in study" (regular follow-up information will be required). The dose adjustments for toxicity and detailed criteria for treatment discontinuation (asciminib in arm A; asciminib or nilotinib in arm B) are specified within the protocol.
  • After the induction of a DMR, the residual disease will be closely monitored by Q-PCR until the fourth year (consolidation phase). During the consolidation phase (2 years) asciminib will be continued at the same dose in both arms; in the combination arm the nilotinib dose will be reduced to 300 mg daily.
  • The patients maintaining a stable MR4 up to the end of the fourth year, that must include in the last year at least 3 evaluable QPCR analyses, will enter the treatment free remission (TFR) phase of the study and will discontinue the treatment (TFR phase). A single unconfirmed loss of MR4 will not preclude the possibility of treatment discontinuation. In case of confirmed loss of MR3 after discontinuation, the choice of subsequent treatment will be up to Local Investigators. The rate of TFR at 5 year (1 year after discontinuation) will be evaluated.
03

Conditions studied

  • CML, Chronic Phase
  • Chronic Myeloid Leukemia, Chronic Phase
  • Chronic Myeloid Leukemia, BCR/ABL-Positive
  • Chronic Myeloid Leukemia

Browse trials for

Keywords

  • asciminib
  • nilotinib
04

In context

Leukemia, Myelogenous, Chronic, BCR-ABL Positive Reclassified

895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.

This study's planned enrollment of 160 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.

Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →

Lead sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto is the lead sponsor of 135 studies on the registry; 36 are open to participants now.

Compared within Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Leukemia, Myeloid, Chronic-Phase. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cytogenetic and molecular confirmed diagnosis of Ph+ and BCR::ABL1+ CML
  • Age ≥ 18 years
  • Early chronic phase, less than 3 months from diagnosis
  • Evidence at the time of study entry of typical BCR::ABL1 RNA transcripts e13a2 or e14a2 (b2a2 or b3a2), which are required for BCR::ABL1 international scale reporting
  • Prior treatment with any TKI for 30 days or less; prior treatment with hydroxyurea or anagrelide is allowed
  • performance status of 0, 1 or 2
  • Adequate end organ function as defined by Total ≤ 1.5 x except for patients with Gilbert's syndrome who may only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN (AST) ≤ 3.0 x ULN Alanine transaminase (ALT) ≤ 3.0 x ULN Serum amylase ≤ ULN Serum lipase ≤ ULN Alkaline phosphatase ≤ 2.5 x ULN, unless considered tumor related > 50 ml/min using Cockcroft-Gault formula
  • Signed written according to ICH/EU/GCP and national local laws prior to any study procedure
  • An effective form of with their sexual partners from enrolment through 30 days after the end of treatment

Exclusion criteria

Exclusion Criteria:

  • CML in blast phase (BP) or in second chronic phase after previous BP, according to WHO criteria
  • Previous treatment with TKIs for more than 30 days
  • Refusal or impossibility to give an
  • History or current diagnosis of cardiac disease indicating significant risk of safety for patients participating in the study such as uncontrolled or significant cardiac disease, including any of the following: recent myocardial infarction (within last 6 months), uncontrolled congestive heart failure, unstable angina (within last 6 months), (symptomatic) cardiac arrhythmias (e.g., sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker).
  • Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection)
  • History of acute pancreatitis within 1 year of study entry or past medical history of chronic pancreatitis
  • History of acute or chronic liver disease
  • History of other active within 2 years prior to study entry with the exception of previous or concomitant basal cell skin cancer and previous carcinoma in situ treated curatively
  • Known history of (HIV), (HBV), or (HCV) infection. Testing for Hepatitis B surface antigen (HBs Ag) and Hepatitis B core antibody (HBc Ab / anti HBc) will be performed at study entry
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
  • Pregnant or lactating women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test.
  • Women of , unless they are using highly effective methods of during dosing and for 30 days after the end of treatment
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Asciminib single agent

    Core phase (2 years): asciminib 80 mg QD will be given as single-agent. Consolidation phase (2 years): If patients will have achieved a DMR (MR4), or if it will be in their interest, the treatment will be continued with asciminib 80 mg QD. Treatment free remission phase (1 year): patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment

    Drug: Asciminib

  • Experimental
    Asciminib plus nilotinib

    Core phase (2 years): asciminib 80 mg QD will be started, then after 90 days asciminib will be given 40 mg BID and nilotinib 300 mg BID, or 300 mg OAD according to the presence/absence of asciminib adverse events, will be added-on. Consolidation phase (2 years): If patients will have achieved a DMR (MR4), or if it will be in their interest, the treatment will be continued with asciminib 40 mg BID and nilotinib reduced to 300 mg daily. Treatment free remission phase (1 year): patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment

    Drug: Asciminib · Drug: Nilotinib

Interventions

  • both arms will include asciminib treatment

  • in the arm B the nilotinib will be added on in all patients

07

What researchers measure

Primary outcomes

  1. evaluation of response of asciminib single-agent or in combination with nilotinib

    Rate of deep molecular response (MR4) achievement

    Time frame: at 2 years

08

Study locations

11 of 11 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Jun 2029, 48 months after the start.

Of 99 non-industry phase 2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 50 and three quarters within 130. This study's planned 48 months is below that.

Counting every sponsor, half of 124 studies reached it within 73 months; a quarter within 42 and three quarters within 121.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2024
First posted
May 10, 2024
StartActual
Jun 26, 2025
Primary completionEst.
Jun 2029
CompletionEst.
Jun 2032
Last update
Jul 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06409936
Collaborators
Grupo Español de Leucemia Mieloide Crónica
Responsible party
Sponsor
First posted
May 10, 2024
Start date
Jun 26, 2025
Primary completion
Jun 2029 (estimated)
Completion
Jun 2032 (estimated)
Last update
Jul 8, 2025

Study contacts

Paola Fazi
Contact
p.fazi@gimema.it
0670390528
Enrico Crea
Contact
e.crea@gimema.it
0670390514
Fausto Castagnetti
principal investigator · "Seragnoli" Institute of Hematology Bologna (Italy)
Valentin Garcia Gutierrez
principal investigator · Hematology Unit, Hospital Universitario Ramón y Cajal, Madrid (Spain)

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Asciminib

Start the discussion